Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
Introduction: MDD represents a significant burden worldwide, and while a number of approved treatments exist, there are high rates of treatment resistance and refractoriness. Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist, is a novel, rapid-acting antidepressant, however the mechanism...
Main Authors: | Madison N. Irwin, PharmD, Amy VandenBerg, PharmD, BCPP |
---|---|
Format: | Article |
Language: | English |
Published: |
American Association of Psychiatric Pharmacists
2021-05-01
|
Series: | Mental Health Clinician |
Subjects: | |
Online Access: | https://theijpt.org/doi/pdf/10.9740/mhc.2021.05.200 |
Similar Items
-
EFFECT OF SINGLE DOSE OF KETAMINE IN PATIENTS OF MAJOR DEPRESSIVE DISORDER-A PAKISTANI PERSPECTIVE
by: Muhammad Siddique Kakar, et al.
Published: (2020-10-01) -
EFFECT OF SINGLE DOSE OF KETAMINE IN PATIENTS OF MAJOR DEPRESSIVE DISORDER-A PAKISTANI PERSPECTIVE
by: Muhammad Siddique Kakar, et al.
Published: (2020-10-01) -
Antipsychotics in child and adolescent patients with major depressive disorder: A retrospective analysis of prescribing patterns
by: Danielle Dauchot, PharmD, et al.
Published: (2024-02-01) -
The molecular pathophysiology of depression and the new therapeutics
by: Haihua Tian, et al.
Published: (2022-09-01) -
Depression-related stigma among primary care providers
by: Andrew Kluemper, PharmD, BCPS, BCPP, et al.
Published: (2021-05-01)